HPSE
Basic information
Region (hg38): 4:83292461-83335153
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HPSE gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 4 | |||||
missense | 30 | 38 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 1 | |||||
Total | 0 | 0 | 30 | 9 | 4 |
Variants in HPSE
This is a list of pathogenic ClinVar variants found in the HPSE region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-83295426-C-T | not specified | Uncertain significance (May 24, 2023) | ||
4-83295427-G-A | not specified | Uncertain significance (Apr 06, 2022) | ||
4-83295453-A-G | not specified | Uncertain significance (Apr 24, 2024) | ||
4-83295481-T-G | not specified | Uncertain significance (Aug 04, 2023) | ||
4-83301004-A-C | HPSE-related disorder | Likely benign (Sep 20, 2022) | ||
4-83301035-A-G | not specified | Uncertain significance (Mar 01, 2024) | ||
4-83301038-C-T | not specified | Likely benign (Nov 30, 2021) | ||
4-83301055-A-G | HPSE-related disorder | Benign (Nov 06, 2019) | ||
4-83301080-G-C | not specified | Uncertain significance (Nov 02, 2023) | ||
4-83302167-A-G | HPSE-related disorder | Likely benign (Aug 12, 2019) | ||
4-83302204-T-C | not specified | Uncertain significance (Jun 18, 2021) | ||
4-83306206-T-A | not specified | Uncertain significance (Nov 17, 2022) | ||
4-83306243-C-T | not specified | Uncertain significance (Nov 18, 2022) | ||
4-83306266-C-T | not specified | Uncertain significance (Jul 26, 2022) | ||
4-83306300-C-T | Likely benign (Jun 23, 2018) | |||
4-83308880-C-T | HPSE-related disorder | Likely benign (Feb 14, 2020) | ||
4-83308885-C-T | not specified | Uncertain significance (May 26, 2024) | ||
4-83308891-C-T | not specified | Uncertain significance (Jan 24, 2023) | ||
4-83309451-T-C | not specified | Uncertain significance (Jan 10, 2023) | ||
4-83309463-T-G | not specified | Uncertain significance (Jul 15, 2021) | ||
4-83309466-T-C | HPSE-related disorder | Benign (Oct 17, 2019) | ||
4-83309473-C-T | not specified | Uncertain significance (Sep 20, 2023) | ||
4-83309479-G-A | not specified | Uncertain significance (May 29, 2024) | ||
4-83310056-C-G | not specified | Uncertain significance (Dec 18, 2023) | ||
4-83310068-C-T | not specified | Uncertain significance (Sep 27, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HPSE | protein_coding | protein_coding | ENST00000405413 | 12 | 42693 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.27e-14 | 0.117 | 125108 | 3 | 636 | 125747 | 0.00254 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.558 | 256 | 282 | 0.907 | 0.0000140 | 3468 |
Missense in Polyphen | 80 | 88.153 | 0.90751 | 1127 | ||
Synonymous | 1.52 | 95 | 116 | 0.820 | 0.00000572 | 1090 |
Loss of Function | 0.878 | 24 | 29.1 | 0.824 | 0.00000153 | 356 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00268 | 0.00265 |
Ashkenazi Jewish | 0.00180 | 0.00169 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.00485 | 0.00486 |
European (Non-Finnish) | 0.00335 | 0.00329 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.00145 | 0.00137 |
Other | 0.00366 | 0.00359 |
dbNSFP
Source:
- Function
- FUNCTION: Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Participates in extracellular matrix (ECM) degradation and remodeling. Selectively cleaves the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. Can also cleave the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying a 2-O-sulfo group, but not linkages between a glucuronic acid unit and a 2-O-sulfated iduronic acid moiety. It is essentially inactive at neutral pH but becomes active under acidic conditions such as during tumor invasion and in inflammatory processes. Facilitates cell migration associated with metastasis, wound healing and inflammation. Enhances shedding of syndecans, and increases endothelial invasion and angiogenesis in myelomas. Acts as procoagulant by increasing the generation of activation factor X in the presence of tissue factor and activation factor VII. Increases cell adhesion to the extracellular matrix (ECM), independent of its enzymatic activity. Induces AKT1/PKB phosphorylation via lipid rafts increasing cell mobility and invasion. Heparin increases this AKT1/PKB activation. Regulates osteogenesis. Enhances angiogenesis through up- regulation of SRC-mediated activation of VEGF. Implicated in hair follicle inner root sheath differentiation and hair homeostasis. {ECO:0000269|PubMed:12213822, ECO:0000269|PubMed:12773484, ECO:0000269|PubMed:15044433, ECO:0000269|PubMed:16452201, ECO:0000269|PubMed:18557927, ECO:0000269|PubMed:18798279, ECO:0000269|PubMed:19244131, ECO:0000269|PubMed:20097882, ECO:0000269|PubMed:20181948, ECO:0000269|PubMed:20309870, ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:21131364}.;
- Pathway
- Proteoglycans in cancer - Homo sapiens (human);Glycosaminoglycan degradation - Homo sapiens (human);Neutrophil degranulation;Metabolism of carbohydrates;HS-GAG degradation;Heparan sulfate/heparin (HS-GAG) metabolism;Glycosaminoglycan metabolism;Innate Immune System;Immune System;Metabolism;Syndecan-1-mediated signaling events
(Consensus)
Recessive Scores
- pRec
- 0.325
Intolerance Scores
- loftool
- 0.994
- rvis_EVS
- 0.02
- rvis_percentile_EVS
- 55.69
Haploinsufficiency Scores
- pHI
- 0.0749
- hipred
- N
- hipred_score
- 0.144
- ghis
- 0.449
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0780
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hpse
- Phenotype
- endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); cellular phenotype; limbs/digits/tail phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; respiratory system phenotype; skeleton phenotype; immune system phenotype;
Gene ontology
- Biological process
- glycosaminoglycan catabolic process;proteoglycan metabolic process;cell-matrix adhesion;positive regulation of vascular endothelial growth factor production;positive regulation of blood coagulation;heparan sulfate proteoglycan catabolic process;positive regulation of osteoblast proliferation;neutrophil degranulation;regulation of hair follicle development;positive regulation of hair follicle development;positive regulation of protein kinase B signaling;angiogenesis involved in wound healing;vascular wound healing
- Cellular component
- extracellular region;nucleus;nucleoplasm;lysosome;lysosomal membrane;extracellular matrix;specific granule lumen;lysosomal lumen;intracellular membrane-bounded organelle;membrane raft
- Molecular function
- beta-glucuronidase activity;protein binding;heparanase activity;syndecan binding;protein dimerization activity